Abbisko Therapeutics Co., Ltd. (Abbisko) aspires to discover and develop differentiated therapeutics for the treatment of cancer diseases. One of Abbisko’s lead products, ABSK-011, is an oral, potent, selective FGFR4 inhibitor. It is currently being investigated in multiple clinical trials, for the treatment of HCC patients with FGF19 overexpression. Our aim is to obtain regulatory approval to make ABSK-011 available to all applicable patients as quickly as possible. As such, we believe participation in clinical trials is the most appropriate way to access ABSK-011 at this stage of development. Information about our clinical trials, including eligibility criteria and locations, are available at clinicaltrials.gov.

Abbisko understands the interest of patients in accessing ABSK-011 outside of clinical trials and prior to regulatory approval for potentially life-threatening HCC, however we do not currently offer any Expanded Access Programs for ABSK-011.

Abbisko recognizes the need for Expanded Access Programs and will re-evaluate the status of our policy based on data from ongoing and future clinical trials.